The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Open accessAbstract
Summary Adenosine (A) to inosine (I) RNA editing introduces many nucleotide changes in cancer transcriptomes. However, due to the complexity of posttranscriptional regulation, the contribution of RNA editing to proteomic diversity in human cancers remains unclear. Here we performed an integrated analysis of TCGA genomic data and CPTAC proteomic data. Despite of limited site diversity, we demonstrate that A-to-I RNA editing contributes to proteomic diversity in breast cancer through changes in amino acid sequences. We validate the presence of editing events at both RNA and protein levels. The edited COPA protein increases proliferation, migration, and invasion of cancer cells in vitro. Our study suggests an important contribution of A-to-I RNA editing to protein diversity in cancer and highlights its translational potential.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Kim, D., Pertea, G., Trapnell, C., Pimentel, H., Kelley, R., & Salzberg, S. L. (2013) · Genome Biology · doi:10.1186/gb-2013-14-4-r36 · Cited by 12,668 · cited 2×
“We mapped FASTQ raw reads with Tophat2 (Kim et al., 2013) and performed the RNA editing analysis in the same way for TCGA RNA-seq BAM files.”
Comprehensive molecular portraits of human breast tumours
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11412 · Cited by 12,129
Genome engineering using the CRISPR-Cas9 system
Ran, F. A., Hsu, P. D., Wright, J., Agarwala, V., Scott, D. A., & Zhang, F. (2013) · Nature Protocols · doi:10.1038/nprot.2013.143 · Cited by 11,133
Comprehensive molecular characterization of human colon and rectal cancer
The Cancer Genome Atlas Network (2012) · Nature · doi:10.1038/nature11252 · Cited by 8,499
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
The I-TASSER Suite: protein structure and function prediction
Yang, J., Yan, R., Roy, A., Xu, D., Poisson, J., & Zhang, Y. (2015) · Nature Methods · doi:10.1038/nmeth.3213 · Cited by 5,596 · cited 2×
“…introduced by COPA_I164V at the atomic level, we first used I-TASSER (http://zhanglab.ccmb.med.umich.edu/I-TASSER/) to generate protein models (Roy et al., 2010; Yang et al., 2015; Zhang, 2008), and selected the representative protein models of the largest cluster in the subsequent analysis.”
I-TASSER server for protein 3D structure prediction
Zhang, Y. (2008) · BMC Bioinformatics · doi:10.1186/1471-2105-9-40 · Cited by 5,124
Predicting Functional Effect of Human Missense Mutations Using PolyPhen‐2
Adzhubei, I., Jordan, D. M., & Sunyaev, S. R. (2013) · Current Protocols in Human Genetics · doi:10.1002/0471142905.hg0720s76 · Cited by 3,705
ProteoWizard: open source software for rapid proteomics tools development
Kessner, D., Chambers, M., Burke, R., Agus, D., & Mallick, P. (2008) · Bioinformatics · doi:10.1093/bioinformatics/btn323 · Cited by 2,024
Proteogenomics connects somatic mutations to signalling in breast cancer
CPTAC, N., Mertins, P., Mani, D. R., Ruggles, K. V., Gillette, M. A., Clauser, K. R., Wang, P., Wang, X., Qiao, J. W., Cao, S., et al. (2016) · Nature · doi:10.1038/nature18003 · Cited by 1,676
Proteogenomic characterization of human colon and rectal cancer
CPTAC, T. N., Zhang, B., Wang, J., Wang, X., Zhu, J., Liu, Q., Shi, Z., Chambers, M. C., Zimmerman, L. J., Shaddox, K. F., et al. (2014) · Nature · doi:10.1038/nature13438 · Cited by 1,462
Harnessing Connectivity in a Large-Scale Small-Molecule Sensitivity Dataset
Seashore-Ludlow, B., Rees, M. G., Cheah, J. H., Cokol, M., Price, E. V., Coletti, M. E., Jones, V., Bodycombe, N. E., Soule, C. K., Gould, J., et al. (2015) · Cancer Discovery · doi:10.1158/2159-8290.cd-15-0235 · Cited by 813 · cited 2×
“org/ctrp/) (Seashore-Ludlow et al., 2015), which included the drug sensitivity data of 481 compounds across 664 cell lines.”
The Genomic Landscape and Clinical Relevance of A-to-I RNA Editing in Human Cancers
Han, L., Diao, L., Yu, S., Xu, X., Li, J., Zhang, R., Yang, Y., Werner, H. M. J., Eterovic, A. K., Yuan, Y., et al. (2015) · Cancer Cell · doi:10.1016/j.ccell.2015.08.013 · Cited by 542 · cited 9×
“For this purpose, we focused on two RNA editing sites (COG3_I635V and COPA_I164V) because (i) COPA_I164V is the only site consistently identified across multiple MS datasets; and (ii) we recently reported the potential functional effects of COG3_I635V on cell viability and drug sensitivity (Han et al., 2015).”
InfluentialSelf-citationREDIportal: a comprehensive database of A-to-I RNA editing events in humans
Picardi, E., D'Erchia, A. M., Lo Giudice, C., & Pesole, G. (2017) · Nucleic Acids Research · doi:10.1093/nar/gkw767 · Cited by 356
Cited by
Neoantigens: promising targets for cancer therapy
Xie, N., Shen, G., Gao, W., Huang, Z., Huang, C., & Fu, L. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01270-x · Cited by 1,020
Cancer vaccines: the next immunotherapy frontier
Lin, M. J., Svensson-Arvelund, J., Lubitz, G. S., Marabelle, A., Melero, I., Brown, B. D., & Brody, J. D. (2022) · Nature Cancer · doi:10.1038/s43018-022-00418-6 · Cited by 843
Ye, L., Zhao, G., Ma, J., Gan, Q., Luo, N., Pan, D., Chen, C., Chen, X., & Ning, S. (2026) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-026-02769-3 · Cited by 10
“73,74 Ex vivo methods typically involve surgical resection of tumor tissue, processing into an immunogenic format, and loading onto APCs before reinfusion.”
Metadata
- Authors
- Peng, X., Xu, X., Wang, Y., Hawke, D. H., Yu, S., Han, L., Zhou, Z., Mojumdar, K., Jeong, K. J., Labrie, M., Tsang, Y. H., Zhang, M., Lu, Y., Hwu, P., Scott, K. L., Liang, H., & Mills, G. B.
- Venue
- Cancer Cell
- Publisher
- Elsevier BV
- Published
- 2018-05
- Volume
- 33
- Issue
- 5
- Pages
- 817-828.e7
- ISSN
- 1535-6108 (ISSN-L)
- OpenAlex
- W2802118789
- Cited by
- 223
- References
- 14
- FWCI
- 7.53
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.